Many proteins involved in cell signaling are phosphorylated. To determine the phosphorylation status of these signaling molecules at the single-cell level, we present a protocol for using state-specific antibodies to detect target phosphoproteins with fluorescence measurements by flow cytometry. To improve the signal intensity, a sandwich-labeling method for the analysis of signaling proteins is performed. By comparing the phosphorylation state of proteins in the presence and absence of sodium pervandate, a nonspecific protein tyrosine phosphatase inhibitor, we determined the relative amount of tyrosine phosphorylated protein in the samples, which reflects the activity of the signaling pathway. This dynamic approach in combination with the signal amplification through a sandwich-labeling method, increased the accuracy and reproducibility of the measurements compared to a single analysis avoiding internal controls defining the maximum level of phosphorylation.
INTRODUCTION
Intracellular phosphorylated proteins (phosphoproteins) are actors in cellular processes, spanning from signal transduction to cell metabolism, cell cycle control, development, and differentiation. The activity of many signaling proteins is regulated by phosphorylation of serine, threonine, or tyrosine residues, or some combination thereof. These phosphorylation changes are posttranslational events that are controlled by the combined action of two opposing enzymes, protein phosphatases and kinases (1) .
The clinical importance of protein phosphorylation is underlined by the fact that several protein kinases have been implicated in cancer as oncogenes, and this activity is antagonized by phosphatases, functioning as tumor suppressors (2) . One example is the phosphatidylinositol 3-kinase (PI3K) to Akt axis a signaling pathway that is controlled by phosphorylation-dephosphorylation mechanisms and appears to be altered in several diseases, including cancer (3) . Tumor cells and immortalized cell lines typically present aberrant activation signaling events compared to those in samples from healthy animals or patients (4) .
Gene expression and protein abundance profiling experiments do not necessarily assess protein activity (5, 6) . For proteins with functions that are controlled by phosphorylation, the experimental determination of residues that can be phosphorylated, as well as their phosphorylation state are important (1) . For proteins that are activated by specific phosphorylation events, measuring the phosphorylation state of the protein is a reliable indicator of activity. Thus, the determination of activation status of intracellular signaling phosphoproteins provides additional layers of information compared with information obtained through transcriptional and protein profiling studies. Methods that facilitate assessment of phosphoprotein status not only contribute to our understanding of cell signaling mechanisms, but may also have roles in the development and implementation of personalized cancer therapies. Methods for ascertaining robust measurements of the phosphorylation state of intracellular signaling proteins in single primary tumor cells with the sensitivity, specificity, and precision are needed to provide clinically useful information.
We present a dynamic phosphoflow proteomic method that uses state-specific antibodies to detect target phosphoproteins by fluorescence-activated cell sorting (FACS). We assess the activity of the signaling pathways following exposure of the cells to either the pleiotropic chemical sodium pervanadate, which inhibits protein tyrosine phosphatases (7) , or to specific kinase inhibitors. For cells exposed to pervanadate, proteins that are relatively unphosphorylated (inactive under basal conditions) will exhibit a large increase in the abundance of the phosphorylated form upon pervanadate treatment; whereas those proteins that are already phosphorylated (active under basal conditions) will exhibit only a limited increase in the abundance of the phosphorylated form following pervanadate treatment (Fig. 1A) . For cells exposed to a specific inhibitor, phosphoflow analysis reveals whether a particular signaling pathway is already activated or not (Fig. 1B) .
In addition, this method can be used to screen new compounds and identify signaling targets in drug discovery. To illustrate both the use of pervanadate and a specific inhibitor, we describe the application of either pervanadate or wortmannin, an antifungal antibiotic that inactivates PI3K (8) to the human monocytic cell line U937 (cells with a PTEN mutation) or the human erythromyeloblastoid leukemia cell line K562 (cells with the Bcr-Abl translocation).
To amplify the signal, we apply a sandwich-labeling method, which involves the application of a biotin-conjugated secondary antibody followed by detection with a fluorescently conjugated streptavidin (Fig. 2) .
We demonstrate the application of this method by analyzing the activity of the PI3K-Akt pathway by measuring the phosphorylation of Akt at Ser 473 and then extend the analysis to other signaling pathways defined by phosphorylation of other signaling components. As with the other methods described above, this Protocol relies on the availability of phosphorylation state-specific antibodies that recognize the target protein.
The technique has the potential to allow the identification of the signaling state of cells from patients, thus facilitating the transformation of the concept of personalized therapy into a clinical reality. 
MATERIALS

Biotin-SP-
Recipe 14: Flow Cytometer Calibration Beads
In a FACS tube, resuspend one drop of (~20 µL) flow cytometer calibration beads into 500 µL of 1× PBS (Recipe 9).
INSTRUCTIONS
Cell Preparation
Cell lines or primary cells may be analyzed by dynamic phosphoflow cytometry. We provide details for the analysis of the human monocytic cell line U937 (cells with a PTEN mutation), the human erythromyeloblastoid leukemia cell line K562 (cells with the Bcr-Abl translocation), and the human T cell line HUT78.
Note: This protocol can be used with primary cells such as peripheral blood mononuclear cells (PBMCs) (from freshly isolated cells or thawed frozen samples).
For commercially available cell lines, we recommend following the supplier's instructions regarding culture medium and growth conditions, for example, any supplements to the growth medium and conditions for passaging the cells. However, it is important that the cells are suspended in a medium with a low concentration of calcium, such as RPMI medium, for analysis. Thus, cells grown in Dulbecco's modified Eagle medium (DMEM) should be transferred to RPMI-based medium when they are collected for analysis.
Ideally, negative-and positive-control cells for which the phosphorylation status of the target protein under the experimental conditions is known, as well as the test cells for which the phosphorylation status of the target protein will be determined, should be analyzed. 18. Add pre-warmed Cytofix/Cytoperm to all samples, mix, and incubate 10 minutes at 37°C.
Note: The volume depends on the number of phosphoproteins to be analyzed. For example, to analyze 5 to 10 phosphoproteins per cell type and per two conditions (UT and treated) in single staining add 100µL (2x10 6 cells) of prewarmed Cytofix/Cytoperm to FACS (UT) and 50µL (1x10 6 cells) to FACS (pV). For a combinaison of 3 fluorochromes in multiparameter phosphoproteins add 115µL (2.3x10 6 cells) to FACS (UT) and 50µL(1x10 6 cells) to FACS (pV).
19. Remove tubes from the water bath and place in a rack at room temperature (RT).
20. Add 1× Perm/Wash Buffer (Recipe 8) to each sample.
Note: The volume depends on the number of phosphoproteins to be analyzed. For example, to analyze 5 to 10 phosphoproteins per cell type and per two conditions (UT and treated) in single staining respectively adjust to 2mL and 4mL with 1× Perm/Wash Buffer to FACS (UT) and to 1mL and 2mL to FACS (pV). For a combinaison of 3 fluorochromes in multiparameter phosphoproteins respectively adjust to 2.3mL and 4.6mL with 1× Perm/Wash Buffer to FACS (UT) and to 1mL and 2mL to FACS (pV).
Wortmannin pretreatment
1. Count the cells using Trypan Blue to determine cell viability.
2. Transfer cell suspension to a 15-mL polystyrene conical centrifuge tube.
3. Centrifuge the cell suspension at 420g for 5 min at 4°C.
4. Resuspend the cell pellet at a final concentration of 1 × 10 6 cells/mL in RPMI-5% FCS (Recipe 2). 10. Transfer cell suspension to 15-mL centrifuge tubes.
Label two wells [untreated cells (UT), inhibitor-treated cells (Inhibitor
11. Centrifuge at 420g for 5 minutes at 4°C.
12. Place the tubes on ice.
13. Remove the supernatant with a suction system.
Resuspend cells in cold RPMI-2% FCS (Recipe 3).
Note 
Antibody Staining
Samples may be permeabilized, fixed, and analyzed following intracellular staining of the target phosphoprotein(s) or the samples may be additionally labelled with antibodies that recognize cell surface markers. This latter staining process is optional, but does allow the cells to be sorted by surface markers.
Cytofix/Cytoperm and Perm/Wash Buffer contain the detergent saponin.
Because saponin-mediated cell permeabilization is a reversible process, it is important to keep the cells in the presence of saponin during both the staining and washing steps.
Staining is performed in 96-well round bottom microtiter plates. To minimize cross-contamination during staining, we recommend that sample-filled wells be surrounded by empty wells on all sides. Negative-and positive-control cells should also be included. To analyze one phosphoprotein per cell type and per inhibitor in a single stain, 3 wells will be prepared ( Fig. 3A ):
• UT sample plus the isotype control antibody
• UT sample plus the antibody against the target phosphoprotein
• Inhibitor-treated sample (pV or Inhibitor) plus the antibody against the target phosphoprotein
To perform labelling of the intracellular phosphoprotein and cell surface markers, then a combination of fluorochromes with nonoverlapping spectra may be used. PE is always used to detect the intracellular phosphoprotein. For example, a combination of 3 fluorochromes may be used and monitored in different channels of the flow cytometer (represented as FLn, where n is the channel number): fluorescein isothiocyanate (FITC) in FL1, PE in FL2, and PE-Cy5 in FL3. We have used a FITC-labeled antibody that recognizes the myeloid surface antigen CD13 and a PE-Cy5-labeled antibody that recognizes the T cell surface antigen CD3. To perform this type of multiparameter analysis and to analyze one phosphoprotein per cell type and per inhibitor 6 wells will be prepared ( Fig. 3B ):
• UT sample plus the isotype control antibody for the FITC-, PE-Cy5-surface directly conjugated antibodies and for PE-intracellular antibody
• UT sample plus the FITC-, PE-Cy5-directly conjugated antibodies against the target surface markers and PE-intracellular antibody against the target phosphoprotein
• Inhibitor-treated sample (pV or Inhibitor) plus the FITC-, PE-Cy5-directly conjugated antibodies against the target surface markers and PE-intracellular antibody against the target phosphoprotein
• UT sample plus FITC-directly conjugated antibody against the target surface marker only (for compensation)
• UT sample plus PE-Cy5-directly conjugated antibody against the target surface marker only (for compensation)
• UT sample plus PE-antibody against the target phosphoprotein only (for compensation) 6. Incubate for 20 min at RT.
7. Centrifuge at RT at 670g for 3 min.
8. Quickly flick into sink and immediately invert the plate on a paper towel .
9. Add 200 µL of Perm/Wash Buffer per well and mix by gently pipetting at least 3 times.
10. Centrifuge at RT at 670g for 3 min.
11. Quickly flick into sink and immediately invert the plate on a paper towel .
12. Add 100 µL of biotin-conjugated secondary antibody solution (Recipe 11) per well and mix by gently pipetting at least 3 times.
13. Incubate for 20 min at RT.
14. Centrifuge at RT at 670g for 3 min.
15. Quickly flick into sink and immediately invert the plate on a paper towel .
16. Add 200 µL of Perm/Wash Buffer per well and mix by gently pipetting at least 3 times.
17. Centrifuge at RT at 670g for 3 min.
18. Quickly flick into sink and immediately invert the plate on a paper towel. 
Staining for surface markers
One fundamental application flow cytometry is the discrimination of cell types based on the differential abundance or presence of surface proteins. Cells may be stained for intracellular phosphorylated proteins and stained for surface markers, allowing differences in signalling responses in mixed populations of cells to be resolved.
Before choosing to label for surface markers, it should be noted that many cell surface markers are sensitive to fixation and permeabilization procedures and will not be recognized by the relevant antibodies afterward such procedures. Thus, we recommend that surface marker labelling under the conditions required for intracellular labelling be tested prior to performing this type of analysis.
In order to perform multiparameter analysis of intracellular and surface proteins, the cell surface antigen must be recognized with antibodies that are directly conjugated to a fluorochrome. The fluorochromes should have minimal spectral overlap. Additional controls are also required compared to the detection of only the intracellular phosphoprotein. The additional controls are necessary for correctly setting compensation parameters, especially if a spectral overlap exists. Single-labeled and multi-labeled controls are needed to ensure correct parameters. They are set to optimize cell number and minimize detector overlap.
1. To the appropriate wells 100 µL of directly conjugated antibody solution (Recipe 13) per well and mix by gently pipetting at least 3 times.
Note: This step follows step 26 in the preceding section.
2. Incubate for 15 min at RT in the dark.
3. Add 150 µL of PBS (Recipe 9) per well and mix by gently pipetting at least 3 times.
4. Centrifuge at RT at 670g for 3 min.
5. Quickly flick into sink and immediately invert the plate on a paper towel.
6. Add 200 µL of PBS (Recipe 9) per well and mix by gently pipetting at least 3 times.
8. Quickly flick into sink and immediately invert the plate on a paper towel.
9. Resuspend the cell pellet in 200 µL of PBS (Recipe 9) and transfer the cell suspension from wells to FACS tubes.
Note: The samples can be stored at 4°C in the dark for 24 hours until flow cytometry acquisition.
Flow Cytometry Analysis
This procedure is based on the use of a FACs Can flow cytometer, but can be adapted to similar equipment. This procedure requires prior familiarity with flow cytometry techniques and instrumentation. 4. Place a FACS tube containing 500 µL Flow Cytometer Calibration Beads (Recipe 9) and acquire about 2,500 events corresponding to single beads in a forward-by-side scatter /side scatter FCS/SSC dot plot using FL2 settings suitable for human test cells (as indicated by FACS supplier's information).
Note: Beads should be mixed well prior to use.
Data acquisition by flow cytometry
Data acquisition parameters depend on if the samples were stained for a single phosphorylated protein or if multiparameter staining was performed. For single staining experiments, a dot plot showing forward-by-side scatter /side scatter (FSC/SSC) is constructed to bring cells on scale, a gate is set around the cell population of interest (possibly all cells), and a histogram showing FL2, the PE channel, is generated to display only events in the defined gate (Fig. 4) .
For multiparameter staining, additional set up is required. In addition to a dot plot showing FSC/SSC for bringing the cells on scale and setting the gates around the cell population of interest (possibly all cells) (Fig. 5A ), a second a dot plot is constructed from the intensity of the staining of the two surface markers. This second dot plot is used to discriminate the different cell types based on the differential expression of surface proteins (Fig. 5B) . Gates are set to identify the population(s) of interest, and then a histogram is constructed showing FL2 to display only events within the corresponding gate (Fig. 5 C,D,E) . A compensation procedure is also necessary. The procedure below assumes that FITC is detected in FL1, PE in FL2, and Cy5 in FL3 and that cells labelled with only a single fluorochrome, such as FITC, PE, or Cy5, are at least as bright, and preferably brighter, than the brightest test samples expected. 4. Start data acquisition in setup mode.
5. If necessary, adjust the FSC and SSC detectors to place the cell populations on the dot plot by first adjusting the voltage settings on the FSC and SSC detectors and then adjusting the threshold to remove "debris" and noncellular elements.
Note: This is done from the flow cytometer menu for the acquisition of cells.
Draw a gate around the cell population of interest (possibly all cells).
6. Refer to the FL2 versus FL1 plot and adjust the voltage on the FL1 detector to position the negative cell population in the first decade of the log scale median fluorescence intensity (MFI) of FL1, then adjust the voltage on the FL2 detector to position the negative cell population in the first decade of the log scale MFI FL2.
7. Refer to FL3 versus FL2 plot and adjust the voltage on the FL3 detector to position the negative cell population in the first decade of log scale MFI FL3.
Note: For single stain refer to the histogram showing FL2 to display only events in the gate and adjust the voltage on the FL2 detector to position the negative cell population in the first decade of the log scale MFI of FL2.
Place a FACS tube containing UT sample plus FITC-directly conjugated antibody against the target surface marker only (for compensation)
Note: Mix cells on a vortex at mediums speed and then introduce samples into the flow cytometer.
9. Refer to the FL2 versus FL1 plot and adjust the FL2-%FL1 compensation control to bring the FITC-only cell population to the point that the FL2 median of this population is approximately the same as the FL2 median of the negative cells.
Note: This is typically moving the cells downward on the plot.
10. Place a FACS tube containing UT sample plus PE-Cy5-directly conjugated antibody against the target surface marker only (for compensation)
Note: Mix cells on a vortex at mediums speed and then introduce samples into the flow cytometer
11. Refer to the FL3 versus FL2 plot and adjust the FL2 -%FL3 compensation control to bring the PE-Cy5-only cell population to the point that the FL2 median of this population is approximately the same as the FL2 median of the negative cells.
Note: This is typically moving the cells leftward on the plot.
Place a FACS tube containing UT sample plus PE-antibody against the target phosphoprotein only (for compensation)
Note: Mix cells on a vortex at mediums speed and then introduce samples into the flow cytometer
13. Refer to the FL2 versus FL1 plot and adjust the FL1 -%FL2 compensation control to bring the PE-only cell population to the point that the FL1 median of this population is approximately the same as the FL1 median of the negative cells.
Note: This is typically moving the cells leftward on the plot.
14. Refer to the FL3 versus FL2 plot and adjust the FL3 -%FL2 compensation control to bring the PE-only labeled cell population to the point that the FL3 median of this population is approximately the same as the FL3 median of the negative cells. 12. Start data acquisition in acquire mode and acquire data for a minimum of 2,500 gated events of a minority cell population of interest.
Note: This is typically moving the cells downward on the plot.
13. Adjust the gate around the cell population of interest (possibly all cells) if necessary.
14. Clean the machine with bleach and water, leave it on standby or shut down.
Note: Data analysis can be performed any time after acquisition has been finished.
Dynamic phosphoflow data analysis
1. From the flow cytometry data analysis software program, create a window with dot plots and histograms (see Fig. 4 and 5 for example) and then open the file to be analyzed.
Note: Once the process has been done once a template can be created for dynamic phosphoflow analysis and used instead of creating a window with the plots and histograms each time.
2. Drag the gates over the correct populations. For single stain, drag the gate over the population in the FSC/SSC dot plot. Set a gate around each population in which you are interested (possibly all cells) and a histogram showing FL2 to display only events in the defined gate (Fig. 4) .
For multicolor stain, drag the gates over the correct populations in the dot plot in which you are interested and histograms showing FL2 to display only events in the above gates (Fig. 5 ). 
7. Construct, in Microsoft Excel, a graph corresponding to relative phosphorylation or to inhibition in function of cell types and phosphoproteins analyzed (see Fig. 6A and B for examples).
RELATED TECHNIQUES
Several methods are available for measuring the phosphorylation analysis (phosphoproteomics) of signaling proteins. Conventional methods, such as immunoprecipitation followed by immunoblotting or immunofluorescence microscopy with antibodies that specifically recognize phosphorylated proteins, have provided a wealth of information about cell signaling, but generally permit the analysis of a few signaling molecules per experiment. Futhermore, these methods have several important limitations (1). The stoichiometry of phosphorylation is usually very low , where all the cells from a cell population are not responding at the same time and/or relative few proteins in the total are phosphorylated. Some signaling molecules are present at low abundance within cells (10) and phosphorylated proteins may be underdetected unless protein phosphatase activity is adequately inhibited during preparation and purification steps of cell lysates. Moreover, these methods are laborious, time consuming, and difficult to adapt for high-throughput analysis (11) .
Mass spectrometry methods overcome many of the limitations of the conventional biochemical techniques (12) (13) (14) . These methods are very powerful to analyze signaling events in large scale into a cell population. However, cells may develop individual flux of signaling events that is buried in the lump of data generated at the cell population level.
Detecting signaling at the single cell level is a critical challenge to probe single cell responses (15) . By using a microfluidics device combined with immunocytochemistry, microfluidics techniques allows analysis based on phosphorylation-specific antibodies and can be applied to single-cell analysis (16) . However, this method has been reported only for adherent-cell signaling experiments.
Phospho-flow proteomics are methods that combine phosphorylation-specific antibodies with flow cytometry. Signaling events are dynamic and phosphorylation sites exist at very low stoichiometric levels (19) . Further confounding analysis, is that , in most cases, phosphorylation is a transient and a reversible event (11) . The consideration of signaling networks as dynamic systems is crucial and requires methods applicable for the analysis of individual living cells (20) .
One way to discern signaling networks that are unique to cancer cells is to expose the cancer cells to potentiating inputs, rather than relying upon the basal amounts of protein phosphorylation alone (21) . Lymphocyte subsets from normal donors exhibit little donor-to-donor variation in cytokine-induced phosphoprotein responses (21) . In contrast, the responses of cells from acute myeloid leukemia (AML) patients varied in numerous ways from one patient to another and were different from normal donors. Our method does not rely on cytokine stimulation and thus should avoid the issues related to donor variability. Just as single-cell phosphoflow proteomics have been used for drug screening by measuring the phosphorylation state of endogenous proteins following exposure to cytokines (18) , our dynamic phosphoflow analysis can also be applied to drug discovery.
NOTES AND REMARKS
We present three examples that illustrate the application of the dynamic phosphoflow method. We performed phosphoflow analysis to determine whether a signaling pathway is constitutively activated (signaling "on") or not (signaling "off") by analyzing the serine phosphorylation of Akt at the position 473 (Ser 473 ) and tyrosine phosphorylation of CrkL at the position 207 (Tyr 207 ) in the T cell line HUT78 that has functional PTEN (phosphatase and tensin homolog) (4, 22) ) and the U937 myeloid cell line that is deficient in PTEN (4, 22) (Fig. 4) . Cells deficient in PTEN exhibit basal activation of the PI3K/ Akt pathway (3). These two cell lines serve ascontrol cells: HUT78 cells should be phosphoAkt negative (PI3K/Akt signaling should be relatively low, "off") and U937 cells should be phosphoAkt positive (PI3K/Akt signaling high, "on").
To show that this method can reveal information about cells for which the state of the signaling pathway is unknown, we compared the results obtained with the U937 and HUT78 cells with those obtained with the chronic myeloid leukaemia (CML) cell line K562 that is PTEN positive, but for which the status of basal phosphorylation of Akt on Ser 473 is controversial (22, 23) . The Akt phosphorylation profile of K562 was similar to the PTEN-deficient cell line, U937 (grey histograms). Moreover, when K562 or U937 cells were treated with pervanadate, the increase in Akt phosphorylation was low, consistent with this pathway active under basal conditions (red curves, Fig. 4B ). Relative phosphorylation, which corresponds to phosphorylation quantitation changes in response to pervanadate, was calculated for the HUT78, U937, and K562 cells. A positive threshold was defined as 0.3, which was based on the mean + 2 standard deviations of relative phosphorylation of the HUT78 cells (Fig. 6A) . Thus, the pathway was considered "on" if the relative phosphorylation values exceeded 0.3. Indeed, the relative phosphorylation values of the U937 and K562 cells were 0.7 and 0.5, respectively, thus, the "test" cells (K562 cells) exhibit basal activity of the PI3K pathway.
The K562 cells also serve as a positive control for analysis of the activity of the oncoprotein tyrosine kinase BCR-ABL, which is present in K562 cells (24) , but not in U937 or HUT78 cells. We assayed the phosphorylation status of the adaptor protein CrkL, which is phosphorylated by BCR-ABL, in these three cell lines and, as expected, high basal phosphorylation of CrkL was only detectable in K562 cells (Fig.  4B ) and the increase of phosphorylation with pervanadate is low (Fig. 4B, red curve  versus grey histogram) . Thus the relative CrkL phosphorylation in K562 cells (calculated as MFI UT/ MFI pV is high (Fig. 6A) .
We also illustrated how with the combination of intracellular phosphorylation-state labeling and extracellular surface marker labeling can differentiate the activity of a signaling pathway in a population of mixed cells. We performed multiparameter labeling by combining direct extracellular staining with intracellular phosphoprotein staining of a mixed cell population containing 20% HUT78 T cells (Akt signaling off, CD3 positive) and 80% U937 myeloid cells (Akt signaling on, CD13 positive) (Fig.  5 ). Cells were treated or not with different agents (wortmannin and pervanadate) and then fixed and permeabilized, stained with antibody against phosphoAkt (Ser 473 ) detected by the sandwich method, and stained with a mixture of antibodies against CD3 (conjugated to PE-Cy5) and CD13 (conjugated to FITC). By selecting all living cells (Fig. 5A) , the HUT78 cells are difficult to detect (Fig. 5C) . However, by selecting independently the two cell types based on their surface markers, CD3 or CD13 (Fig. 5B) , the cell-specific status of the phosphorylation of Akt Ser 473 becomes resolvable ( Fig. 5D-E) . Moreover, treatment of the cells with the PI3K inhibitor (wortmannin) does not change the Akt Ser 473 phosphorylation status in HUT78 cells (Fig. 5E , blue curve versus grey histogram), but substantially decreases the basal Akt Ser 473 phosphorylation state in U937 cells (Fig. 5D , blue curve versus grey histogram).
To demonstrate the potential usefulness in drug development and assessment of the specificity of inhibitor activity, we examined the effects of wortmannin on the phosphorylation of the BCR-ABL target CrkL, which is not known as downstream of PI3K. The high phosphorylation of Akt in U937 and K562 cells was largely decreased (Fig. 7 , upper histograms) by wortmannin; however, wortmannin failed to decrease the phosphorylation CrkL in K562 cells (Fig.7, lower histograms) , showing that WMN doesn't affect the Bcr-Abl tyrosine kinase activity in K562 cells. Phosphorylation inhibition was quantified (Fig. 6B) . A positive threshold was defined from on the basis of the HUT78 cells as 51%, which is consistent with previously considered threshold (25) . The percent inhibition in the U937 and K562 cells exceeded this threshold at 76% and 77%, respectively. Thus, both the pervanadate data and the wortmannin data suggest that Akt is basally active in these cells and the wortmannin data further suggest that PI3K is implicated in the phosphorylation of Akt Ser 473 .
These examples illustrate the potential utility of this protocol to investigate the basal activaty of signaling pathways at the single-cell level, to develop kinase-or phosphatase-targeted drugs, and elucidate potential new targets of existing drugs. This dynamic approach by modulation positive and negative of kinases and phosphatases that are involved in signaling cascades, in combination with the signal amplification through a sandwich labeling method, increases the accuracy and reproducibility of the measurements compared to a single analysis without treatment with pleitropic activators of signaling pathways. 
